The drugmaker said a U.S. federal jury found that Avilar Therapeutics and RA Capital Management willfully and maliciously stole a trade secret technology developed at Yale University related to targeted protein degradation.
Biohaven licensed Yale's MODA targeted protein degradation platform and holds rights to develop and commercialize the technology.
The jury also found RA Capital breached a 2019 confidentiality agreement with Yale.
The jury awarded $2 million to Yale for contract breach and $1 million each to Yale and Biohaven for trade-secret misappropriation.
Biohaven and Yale argued that RA Capital used the information to help build competing drug-developer Avilar.
The suit was filed against Avilar and RA Capital in March 2023 in the U.S. District Court for the District of Delaware.
As of the last close, BHVN was up 30% year to date.
BHVN•
